Evidence map›Paper›PMID 42452550›Full record

ArticleJournal of clinical medicine2026

Promoter Methylation and Somatic Mutations in Cancer-Related Genes Are Associated with Hyperprogressive Disease in Patients with Malignant Melanoma and Renal Cell Carcinoma Receiving Anti-PD-1/PD-L1 Immunotherapy.

Adem Deligonul, Mehmet Sarimahmut, Ahmet Bilgehan Sahin, Elif Erturk, Engin Atli, Hazal Sezginer Guler, Erdem Cubukcu, Hulya Ozturk Nazlioglu, Saduman Balaban Adim, Turkkan Evrensel and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Adem DeligonulDepartment of Medical Oncology, School of Medicine, Bursa Uludag University, 16059 Bursa, Turkey.ORCID 0009-0001-3931-0191
Mehmet SarimahmutDepartment of Biology, Faculty of Science and Arts, Bursa Uludag University, 16059 Bursa, Turkey.ORCID 0000-0003-2647-5875
Ahmet Bilgehan SahinDepartment of Medical Oncology, School of Medicine, Bursa Uludag University, 16059 Bursa, Turkey.ORCID 0000-0002-7846-0870
Elif ErturkVocational School of Health Services, Bursa Uludag University, 16059 Bursa, Turkey.ORCID 0000-0001-7668-796X
Engin AtliDepartment of Medical Genetics, Faculty of Medicine, Trakya University, 22030 Edirne, Turkey.
Hazal Sezginer GulerDepartment of Medical Genetics, Faculty of Medicine, Trakya University, 22030 Edirne, Turkey.ORCID 0000-0003-3993-1374
Erdem CubukcuDepartment of Medical Oncology, School of Medicine, Bursa Uludag University, 16059 Bursa, Turkey.
Hulya Ozturk NazliogluDepartment of Pathology, School of Medicine, Bursa Uludag University, 16059 Bursa, Turkey.
Saduman Balaban AdimDepartment of Pathology, School of Medicine, Bursa Uludag University, 16059 Bursa, Turkey.
Turkkan EvrenselDepartment of Medical Oncology, School of Medicine, Bursa Uludag University, 16059 Bursa, Turkey.ORCID 0000-0002-9732-5340
Ferda AriDepartment of Biology, Faculty of Science and Arts, Bursa Uludag University, 16059 Bursa, Turkey.ORCID 0000-0002-6729-7908

Funding

Bursa Uludağ Üni̇versi̇tesi̇ TGA-2021-318
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

hyperprogressive diseaseimmune checkpoint inhibitorsmalignant melanomanext-generation sequencingpromoter methylationrenal cell carcinoma

Identifiers

PMID42452550
PMCPMC13362896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.